2021

1. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

   Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146